Drug intelligence / Profile preview

Shengeke Pharmaceuticals PROTAC

Development stage: Preclinical
Lead developer: Shengke Pharmaceuticals Ltd.
Modality: PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules

Overview

Shengeke Pharmaceuticals is developing a preclinical-stage proteolysis-targeting chimera (PROTAC) for the treatment of solid tumors. As a PROTAC, the molecule is designed to facilitate the degradation of a specific, though currently undisclosed, target protein by recruiting an E3 ubiquitin ligase to the target, leading to its ubiquitination and subsequent degradation by the proteasome. This program is part of Shengeke's broader oncology portfolio, which focuses on small molecule dual inhibitors and targeted therapies.

Beyond the preview

Go deeper on Shengeke Pharmaceuticals PROTAC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shengeke Pharmaceuticals PROTAC.

Explore the full profile